Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Torray Investment Partners LLC

Torray Investment Partners LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,008 shares of the pharmaceutical company’s stock after acquiring an additional 257 shares during the quarter. Torray Investment Partners LLC’s holdings in Vertex Pharmaceuticals were worth $6,446,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of VRTX. Focus Financial Network Inc. lifted its stake in shares of Vertex Pharmaceuticals by 7.1% in the third quarter. Focus Financial Network Inc. now owns 558 shares of the pharmaceutical company’s stock worth $260,000 after acquiring an additional 37 shares in the last quarter. Chicago Partners Investment Group LLC lifted its stake in shares of Vertex Pharmaceuticals by 6.5% in the third quarter. Chicago Partners Investment Group LLC now owns 475 shares of the pharmaceutical company’s stock worth $223,000 after acquiring an additional 29 shares in the last quarter. Van ECK Associates Corp lifted its stake in shares of Vertex Pharmaceuticals by 4.5% in the third quarter. Van ECK Associates Corp now owns 151,428 shares of the pharmaceutical company’s stock worth $71,179,000 after acquiring an additional 6,588 shares in the last quarter. Intact Investment Management Inc. acquired a new stake in Vertex Pharmaceuticals during the third quarter valued at approximately $326,000. Finally, Vestor Capital LLC raised its stake in Vertex Pharmaceuticals by 16.4% during the third quarter. Vestor Capital LLC now owns 362 shares of the pharmaceutical company’s stock valued at $168,000 after buying an additional 51 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 310 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the sale, the executive vice president now owns 64,021 shares in the company, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 1,084 shares of company stock valued at $505,512. 0.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have issued reports on VRTX shares. UBS Group upped their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Citigroup started coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $575.00 price objective on the stock. Truist Financial upped their price objective on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, StockNews.com cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $483.31 on Tuesday. The stock has a fifty day moving average price of $441.95 and a two-hundred day moving average price of $461.06. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a market cap of $124.11 billion, a P/E ratio of -219.69, a PEG ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.